ABBVIE
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 426
- Registration Number
- NCT04994535
- Locations
- 🇺🇸
Westside Aesthetics /ID# 231196, Los Angeles, California, United States
🇺🇸DeNova Research /ID# 231191, Chicago, Illinois, United States
🇺🇸Skin and Cancer Associates, LLP /ID# 231189, Miami, Florida, United States
A Study to Evaluate an Updated Dexamethasone Intravitreal (Into the Eye) Applicator in Adult Participants With Macular Edema Due to Diseases of the Retina
- Conditions
- Interventions
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 54
- Registration Number
- NCT04976777
- Locations
- 🇺🇸
North Texas Retina Consultants /ID# 241013, Willow Park, Texas, United States
🇺🇸Global Research Management /ID# 238944, Glendale, California, United States
🇺🇸Retina Research Institute of Texas /ID# 231420, Abilene, Texas, United States
A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154
- Conditions
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 181
- Registration Number
- NCT04972968
- Locations
- 🇭🇺
Kistarcsai Flor Ferenc Korhaz /ID# 229676, Kistarcsa, Hungary
🇯🇵Kuwana city medical center /ID# 231936, Kuwana-shi, Mie, Japan
🇪🇸Hospital Universitario Marques de Valdecilla /ID# 229297, Santander, Cantabria, Spain
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
- Conditions
- Interventions
- First Posted Date
- 2021-07-16
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04965272
- Locations
- 🇺🇸
ATP Clinical Research, Inc /ID# 230445, Costa Mesa, California, United States
🇺🇸FutureSearch Trials of Dallas, LP /ID# 230535, Dallas, Texas, United States
🇺🇸Anderson Clinical Research /ID# 230440, Redlands, California, United States
Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 63
- Registration Number
- NCT04949828
- Locations
- 🇺🇸
John Hopkins University /ID# 227061, Baltimore, Maryland, United States
🇺🇸Baylor College of Medicine - Baylor Medical Center /ID# 227067, Houston, Texas, United States
🇺🇸NYU Langone Health /ID# 230818, New York, New York, United States
A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 408
- Registration Number
- NCT04949399
- Locations
- 🇺🇸
Laser and Skin Surgery Center of Indiana /ID# 229515, Indianapolis, Indiana, United States
🇺🇸Advanced Research Associates - Glendale /ID# 229256, Glendale, Arizona, United States
🇺🇸Clinical Testing of Beverly Hills /ID# 229946, Encino, California, United States
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 185
- Registration Number
- NCT04927975
- Locations
- 🇺🇸
Duplicate_UMass Chan Medical School /ID# 228066, Worcester, Massachusetts, United States
🇺🇸Duplicate_Michigan Center for Research Company /ID# 228054, Clarkston, Michigan, United States
🇺🇸Oregon Medical Research Center /ID# 228073, Portland, Oregon, United States
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 698
- Registration Number
- NCT04928846
- Locations
- 🇿🇦
Steve Biko Academic Hospital /ID# 230883, Pretoria, Gauteng, South Africa
🇺🇸University of Alabama at Birmingham - Main /ID# 247074, Birmingham, Alabama, United States
🇺🇸Ironwood Cancer & Res Ctr /ID# 262446, Chandler, Arizona, United States
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
- Conditions
- Interventions
- First Posted Date
- 2021-06-04
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 153
- Registration Number
- NCT04913610
- Locations
- 🇨🇩
Hôpital Général de Référence de Kimpese, Kimpese, Kongo Central, Congo, The Democratic Republic of the
🇨🇩Hôpital Général de Référence de Masi-Manimba, Masi-Manimba, Kwilu, Congo, The Democratic Republic of the
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 40
- Registration Number
- NCT04912063
- Locations
- 🇮🇱
Hadassah Medical Center-Hebrew University /ID# 227275, Jerusalem, Yerushalayim, Israel
🇦🇺Austin Health /ID# 227717, Heidelberg, Victoria, Australia
🇮🇱Rabin Medical Center /ID# 227738, Petakh Tikva, Israel